Zobrazeno 1 - 10
of 253
pro vyhledávání: '"C. Oliver Hanemann"'
Autor:
Laurien L. van de Weijer, Emanuela Ercolano, Ting Zhang, Maryam Shah, Matthew C. Banton, Juri Na, Claire L. Adams, David Hilton, Kathreena M. Kurian, C. Oliver Hanemann
Publikováno v:
Acta Neuropathologica Communications, Vol 11, Iss 1, Pp 1-24 (2023)
Abstract Meningiomas are the most common intracranial brain tumours. These tumours are heterogeneous and encompass a wide spectrum of clinical aggressivity. Treatment options are limited to surgery and radiotherapy and have a risk of post-operative m
Externí odkaz:
https://doaj.org/article/cd48f2dd0ffc49a5a1aa1e6ce36dba3d
Autor:
Jemma Dunn, Sara Ferluga, Vikram Sharma, Matthias Futschik, David A. Hilton, Claire L. Adams, Edwin Lasonder, C. Oliver Hanemann
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 77-91 (2019)
Background: Meningioma is the most frequent primary intracranial tumour. Surgical resection remains the main therapeutic option as pharmacological intervention is hampered by poor knowledge of their proteomic signature. There is an urgent need to ide
Externí odkaz:
https://doaj.org/article/941610315eae44c99a420e489e4450af
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 8 (2020)
BackgroundA wide range of human in vitro methods have been developed and there is considerable interest in the potential of these studies to address questions related to clinical (human) use of drugs, and the pathobiology of tumours. This requires ag
Externí odkaz:
https://doaj.org/article/4595ec634ffd49949e318706e9103ce7
Autor:
Agbolahan A. Sofela, David A. Hilton, Sylwia Ammoun, Daniele Baiz, Claire L. Adams, Emanuela Ercolano, Michael D. Jenkinson, Kathreena M. Kurian, Mario Teo, Peter C. Whitfield, Felix Sahm, C. Oliver Hanemann
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 2, p 560 (2021)
There is an unmet need for the identification of biomarkers to aid in the diagnosis, clinical management, prognosis and follow-up of meningiomas. There is currently no consensus on the optimum management of WHO grade II meningiomas. In this study, we
Externí odkaz:
https://doaj.org/article/3dae689aa11945d7b6afce57548e0e4b
Autor:
Jemma Dunn, Vasileios P. Lenis, David A. Hilton, Rolf Warta, Christel Herold-Mende, C. Oliver Hanemann, Matthias E. Futschik
Publikováno v:
Cancers, Vol 12, Iss 11, p 3270 (2020)
Meningioma are the most frequent primary intracranial tumour. Management of aggressive meningioma is complex, and development of effective biomarkers or pharmacological interventions is hampered by an incomplete knowledge of molecular landscape. Here
Externí odkaz:
https://doaj.org/article/bbf9358c1ec946b4831ab3322e66f788
Autor:
Claire L. Adams, Emanuela Ercolano, Sara Ferluga, Agbolahan Sofela, Foram Dave, Caterina Negroni, Kathreena M. Kurian, David A. Hilton, C. Oliver Hanemann
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 4, p 1273 (2020)
The majority of meningiomas are grade I, but some grade I tumours are clinically more aggressive. Recent advances in the genetic study of meningiomas has allowed investigation into the influence of genetics on the tumour microenvironment, which is im
Externí odkaz:
https://doaj.org/article/d70bcb4870094364ba9c2098d4b3d87f
Publikováno v:
Neurobiology of Disease, Vol 37, Iss 1, Pp 141-146 (2010)
Deficiency of the tumor suppressor merlin leads to the development of multiple tumors of the nervous system, such as schwannomas, meningiomas, and ependymomas. Due to the benign character of these tumors, classical chemotherapy is ineffective. Curren
Externí odkaz:
https://doaj.org/article/852e20d88bcb4f2e86233d736e914daf
Publikováno v:
Neurobiology of Disease, Vol 19, Iss 1, Pp 1-9 (2005)
Loss of the tumor suppressor protein merlin causes a variety of benign tumors such as schwannomas, meningiomas, and gliomas in man. We previously reported primary human schwannoma cells to show enhanced integrin-dependent adhesion and a hyperactivati
Externí odkaz:
https://doaj.org/article/4bbcadf22cfc4af8ae5f3dd8bb3833b4
Autor:
Filippo G. Giancotti, C. Oliver Hanemann, Matthias A. Karajannis, Charles M. Rudin, Marjorie Zauderer, John T. Poirier, Elisa de Stanchina, Kamalika Moulick, Virginia Ojeda, Milica Pavlovic, Lu Zhou, Qingwen Xu, Jonathan Cooper
Figure S1 related to Figure 1 shows that MLN4924 reduces oligo-ubiquitylation of Lats2 and that Merlin-mutant schwannoma cells have a lower on-target sensitivity to MLN4924 than a genetically matched Merlin-positive Schwann line. Also shows that cano
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e005f44f985c91c690f2f7d144eb590
https://doi.org/10.1158/1535-7163.22509973.v1
https://doi.org/10.1158/1535-7163.22509973.v1
Autor:
Filippo G. Giancotti, C. Oliver Hanemann, Matthias A. Karajannis, Charles M. Rudin, Marjorie Zauderer, John T. Poirier, Elisa de Stanchina, Kamalika Moulick, Virginia Ojeda, Milica Pavlovic, Lu Zhou, Qingwen Xu, Jonathan Cooper
Supplementary Materials and Methods, Supplementary Figure Legends, Supplementary Table 1, Supplementary References
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90bb5f96cc57d9dc1bdd6b813c9e635b
https://doi.org/10.1158/1535-7163.22509958
https://doi.org/10.1158/1535-7163.22509958